Bristol-Myers Boosts 2026 Guidance on Portfolio Strength
Bristol-Myers beats Q2 earnings and revenue estimates, driven by growth drugs, while raising its full-year 2026 sales and profit outlook.
Bristol-Myers did better than expected this quarter and now thinks it will make more money next year because its medicines are selling well. When a company feels confident enough to promise higher earnings, it usually means people trust the business is working.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.